Back to search results

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Abroad (travel likely)RecruitingPHASE2

Conditions

Neuroendocrine Tumors · NET · Pancreatic Neuroendocrine Tumor · Gastrointestinal Neuroendocrine Tumor · Pulmonary Neuroendocrine Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

    Contact: Study coordinator (Jason Ledesma) · Jason.ledesma@haog.org
    Contact: Principal Investigator (Michael Demeure, MD)

  • Rocky Mountain Cancer Centers, Denver, Colorado, United States

    Contact: Study coordinator (Jennifer Hedge) · jennifer.hege@usoncology.com
    Contact: Principal Investigator (Allen Cohn, MD)

  • Texas Oncology, Dallas, Texas, United States

    Contact: Study coordinator (Christine Terraciano) · christine.terraciano@usoncology.com
    Contact: Principal Investigator (Scott Paulson, MD)

  • Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States

    Contact: Study coordinator (Barbara A Dion, CCRC) · badion@mcw.edu · 414-805-4639
    Contact: Principal Investigator (Alexandria T Phan, MD)
Study leads

  • Willis Navarro, MD

    Study Director

    Aadi Bioscience

View source on ClinicalTrials.gov(opens in a new tab)